NCT06085755
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
At risk: Primary completion moved at least 1 year 11 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 2025 to Dec 1, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 65 words
- Enrollment closed, study ongoing
- Study completion pushed from Dec 2026 to Dec 1, 2028
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Oct 2024 to Sep 30, 2024
- Notable Start date: Jun 2024 to Oct 2024v4
- Notable Start date: Dec 2023 to Jun 2024v3
- Notable Start date: Oct 2023 to Dec 2023
- Primary completion date: Oct 2025 to Dec 2025
- Study completion date: Oct 2026 to Dec 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
The first part (PART A) will be in combination with T-DXd the starting dose of 20 mg afatinib MWF will be escalated to reach a maximum tolerated dose in patients with advanced gastric cancer patients with HER2-low, as defined by dose-limiting toxicity. The second part (PART B) will be expansion cohort, in which Afatinib will be taken in combination with T-DXd according to the recommended Phase 2 dose(RP2D) confirmed through Part A from cycle 1.
Drugs: Trastuzumab deruxtecan, Afatinib
Sites
1 site in 1 country
- Samsung Medical CenterSeoul, South Korea